MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-120
Shots:
- MindMed gets access to Catalent’s Zydis technology for the development of MindMed’s MM-120 (lysergide D-tartrate) & also gets an exclusive right for the use of the Zydis technology to develop all salt and polymorphic forms of lysergide in the US, UK, and EU among other key territories
- Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses instantly in the mouth without needing water. MM-120 is currently being studied in the P-IIb trial for generalized anxiety disorder (GAD) with expected results in Q4’23
- Additionally, MindMed continues to advance MM-120 ODT formulation into pivotal clinical trials & seeks to initiate a P-I PK bridging study
Ref: Businesswire | Image: MindMed
Related News:- Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
